This narrative review maps next-generation anti-obesity agents, ultralong-acting incretins, oral formulations, multi-receptor agonists, and lean-mass-sparing pathways, giving endocrinology and obesity pharmacists a forward view of the pipeline.
Innovative anti-obesity drugs offer hope beyond current treatments.
Obesity is a growing global issue with current treatments presenting challenges like adverse effects and rebound weight gain, highlighting the need for new therapies. The review identifies potential non-incretin pharmacological targets and novel anti-obesity drug candidates for further clinical validation. While promising, these emerging therapies require more clinical trials to assess their safety and efficacy compared to current options before influencing practice. New non-incretin anti-obesity drugs are on the horizon, offering hope for safer, more effective treatments.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Lee S, Song H, Kwon Y A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel, Switzerland). 2026;19(7). doi:10.3390/ph19071047
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.